|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SERTAD2 |
Gene summary for SERTAD2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SERTAD2 | Gene ID | 9792 |
| Gene name | SERTA domain containing 2 | |
| Gene Alias | Sei-2 | |
| Cytomap | 2p14 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | Q14140 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9792 | SERTAD2 | LZE2T | Human | Esophagus | ESCC | 1.46e-03 | 2.46e-01 | 0.082 |
| 9792 | SERTAD2 | LZE4T | Human | Esophagus | ESCC | 5.92e-19 | 6.02e-01 | 0.0811 |
| 9792 | SERTAD2 | LZE5T | Human | Esophagus | ESCC | 3.53e-03 | 3.46e-01 | 0.0514 |
| 9792 | SERTAD2 | LZE7T | Human | Esophagus | ESCC | 1.68e-08 | 6.77e-01 | 0.0667 |
| 9792 | SERTAD2 | LZE8T | Human | Esophagus | ESCC | 6.27e-13 | 4.24e-01 | 0.067 |
| 9792 | SERTAD2 | LZE20T | Human | Esophagus | ESCC | 7.12e-06 | 3.04e-01 | 0.0662 |
| 9792 | SERTAD2 | LZE21D1 | Human | Esophagus | HGIN | 4.59e-02 | 2.56e-01 | 0.0632 |
| 9792 | SERTAD2 | LZE22T | Human | Esophagus | ESCC | 1.20e-03 | 3.21e-01 | 0.068 |
| 9792 | SERTAD2 | LZE24T | Human | Esophagus | ESCC | 8.49e-19 | 4.90e-01 | 0.0596 |
| 9792 | SERTAD2 | LZE21T | Human | Esophagus | ESCC | 4.74e-09 | 7.30e-01 | 0.0655 |
| 9792 | SERTAD2 | LZE6T | Human | Esophagus | ESCC | 2.23e-05 | 2.28e-01 | 0.0845 |
| 9792 | SERTAD2 | P1T-E | Human | Esophagus | ESCC | 7.01e-14 | 9.16e-01 | 0.0875 |
| 9792 | SERTAD2 | P2T-E | Human | Esophagus | ESCC | 4.22e-51 | 8.85e-01 | 0.1177 |
| 9792 | SERTAD2 | P4T-E | Human | Esophagus | ESCC | 1.00e-23 | 5.13e-01 | 0.1323 |
| 9792 | SERTAD2 | P5T-E | Human | Esophagus | ESCC | 2.98e-17 | 2.42e-01 | 0.1327 |
| 9792 | SERTAD2 | P8T-E | Human | Esophagus | ESCC | 7.80e-18 | 2.65e-01 | 0.0889 |
| 9792 | SERTAD2 | P9T-E | Human | Esophagus | ESCC | 4.90e-09 | 2.22e-01 | 0.1131 |
| 9792 | SERTAD2 | P10T-E | Human | Esophagus | ESCC | 1.44e-17 | 2.86e-01 | 0.116 |
| 9792 | SERTAD2 | P11T-E | Human | Esophagus | ESCC | 2.35e-17 | 7.61e-01 | 0.1426 |
| 9792 | SERTAD2 | P12T-E | Human | Esophagus | ESCC | 2.37e-26 | 6.59e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00063687 | Esophagus | HGIN | transcription elongation from RNA polymerase II promoter | 24/2587 | 69/18723 | 8.93e-06 | 2.64e-04 | 24 |
| GO:00063548 | Esophagus | HGIN | DNA-templated transcription, elongation | 27/2587 | 91/18723 | 6.62e-05 | 1.52e-03 | 27 |
| GO:001604919 | Esophagus | HGIN | cell growth | 93/2587 | 482/18723 | 4.49e-04 | 6.62e-03 | 93 |
| GO:000155818 | Esophagus | HGIN | regulation of cell growth | 76/2587 | 414/18723 | 5.40e-03 | 4.42e-02 | 76 |
| GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
| GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
| GO:000636814 | Esophagus | ESCC | transcription elongation from RNA polymerase II promoter | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
| GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
| GO:00400295 | Esophagus | ESCC | regulation of gene expression, epigenetic | 74/8552 | 105/18723 | 2.24e-07 | 3.42e-06 | 74 |
| GO:00459267 | Esophagus | ESCC | negative regulation of growth | 148/8552 | 249/18723 | 7.88e-06 | 7.73e-05 | 148 |
| GO:00480962 | Esophagus | ESCC | chromatin-mediated maintenance of transcription | 11/8552 | 11/18723 | 1.80e-04 | 1.16e-03 | 11 |
| GO:00303085 | Esophagus | ESCC | negative regulation of cell growth | 108/8552 | 188/18723 | 7.46e-04 | 3.87e-03 | 108 |
| GO:0045815 | Esophagus | ESCC | positive regulation of gene expression, epigenetic | 13/8552 | 17/18723 | 1.00e-02 | 3.42e-02 | 13 |
| GO:00160495 | Liver | NAFLD | cell growth | 85/1882 | 482/18723 | 1.75e-07 | 1.25e-05 | 85 |
| GO:00015585 | Liver | NAFLD | regulation of cell growth | 63/1882 | 414/18723 | 5.50e-04 | 7.46e-03 | 63 |
| GO:001604911 | Liver | Cirrhotic | cell growth | 160/4634 | 482/18723 | 1.50e-05 | 2.07e-04 | 160 |
| GO:000155811 | Liver | Cirrhotic | regulation of cell growth | 132/4634 | 414/18723 | 5.53e-04 | 4.36e-03 | 132 |
| GO:00063544 | Liver | Cirrhotic | DNA-templated transcription, elongation | 35/4634 | 91/18723 | 2.56e-03 | 1.53e-02 | 35 |
| GO:00063683 | Liver | Cirrhotic | transcription elongation from RNA polymerase II promoter | 28/4634 | 69/18723 | 2.70e-03 | 1.58e-02 | 28 |
| GO:001604921 | Liver | HCC | cell growth | 269/7958 | 482/18723 | 1.84e-09 | 5.35e-08 | 269 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SERTAD2 | SNV | Missense_Mutation | c.897N>A | p.Met299Ile | p.M299I | Q14140 | protein_coding | tolerated(0.37) | benign(0.003) | TCGA-A8-A06T-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| SERTAD2 | SNV | Missense_Mutation | novel | c.62T>C | p.Ile21Thr | p.I21T | Q14140 | protein_coding | tolerated(0.34) | benign(0.003) | TCGA-AQ-A54N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SERTAD2 | insertion | Nonsense_Mutation | novel | c.831_832insCCAGAAGGCATCCATCATGTTGCTTAATTGTCTTCTGCAGCTCCATAATATATT | p.Asp277_Asp278insProGluGlyIleHisHisValAlaTerLeuSerSerAlaAlaProTerTyrIle | p.D277_D278insPEGIHHVA*LSSAAP*YI | Q14140 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| SERTAD2 | deletion | Frame_Shift_Del | novel | c.844delN | p.Thr282LeufsTer51 | p.T282Lfs*51 | Q14140 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| SERTAD2 | deletion | Frame_Shift_Del | novel | c.112delN | p.Gln38ArgfsTer9 | p.Q38Rfs*9 | Q14140 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| SERTAD2 | SNV | Missense_Mutation | rs377127082 | c.332C>T | p.Ala111Val | p.A111V | Q14140 | protein_coding | tolerated(0.17) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SERTAD2 | SNV | Missense_Mutation | novel | c.554N>T | p.Ser185Phe | p.S185F | Q14140 | protein_coding | deleterious(0.03) | possibly_damaging(0.77) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SERTAD2 | SNV | Missense_Mutation | novel | c.548C>T | p.Ser183Phe | p.S183F | Q14140 | protein_coding | deleterious(0.02) | possibly_damaging(0.459) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| SERTAD2 | insertion | Frame_Shift_Ins | novel | c.811_812insA | p.Met271AsnfsTer108 | p.M271Nfs*108 | Q14140 | protein_coding | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SERTAD2 | SNV | Missense_Mutation | rs760388077 | c.595A>G | p.Thr199Ala | p.T199A | Q14140 | protein_coding | tolerated(0.77) | benign(0) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |